Novavax Statistics

Total Valuation

Novavax has a market cap or net worth of MXN 20.33 billion. The enterprise value is 11.00 billion.

Market Cap	20.33B
Enterprise Value	11.00B

Important Dates

The last earnings date was Thursday, November 6, 2025.

Earnings Date	Nov 6, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	162.50M
Shares Outstanding	n/a
Shares Change (YoY)	+16.16%
Shares Change (QoQ)	-8.39%
Owned by Insiders (%)	0.51%
Owned by Institutions (%)	52.21%
Float	134.90M

Valuation Ratios

The trailing PE ratio is 3.24.

PE Ratio	3.24
Forward PE	n/a
PS Ratio	1.04
PB Ratio	-7.07
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 1.33, with an EV/FCF ratio of -1.56.

EV / Earnings	1.75
EV / Sales	0.57
EV / EBITDA	1.33
EV / EBIT	1.45
EV / FCF	-1.56

Financial Position

The company has a current ratio of 2.27

Current Ratio	2.27
Quick Ratio	1.85
Debt / Equity	n/a
Debt / EBITDA	0.56
Debt / FCF	-0.65
Interest Coverage	13.84

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	18.01%
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	55.57%
Revenue Per Employee	20.51M
Profits Per Employee	6.58M
Employee Count	952
Asset Turnover	0.74
Inventory Turnover	39.01

Taxes

In the past 12 months, Novavax has paid 163.94 million in taxes.

Income Tax	163.94M
Effective Tax Rate	2.55%

Stock Price Statistics

The stock price has decreased by -29.14% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-29.14%
50-Day Moving Average	146.80
200-Day Moving Average	145.85
Relative Strength Index (RSI)	39.10
Average Volume (20 Days)	762

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	11.87

Income Statement

In the last 12 months, Novavax had revenue of MXN 19.53 billion and earned 6.27 billion in profits. Earnings per share was 37.98.

Revenue	19.53B
Gross Profit	11.60B
Operating Income	7.65B
Pretax Income	6.43B
Net Income	6.27B
EBITDA	8.29B
EBIT	7.65B
Earnings Per Share (EPS)	37.98

Full Income Statement

Balance Sheet

The company has 13.99 billion in cash and 4.61 billion in debt, giving a net cash position of 9.39 billion.

Cash & Cash Equivalents	13.99B
Total Debt	4.61B
Net Cash	9.39B
Net Cash Per Share	n/a
Equity (Book Value)	-2.87B
Book Value Per Share	-17.69
Working Capital	9.99B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -6.94 billion and capital expenditures -99.34 million, giving a free cash flow of -7.04 billion.

Operating Cash Flow	-6.94B
Capital Expenditures	-99.34M
Free Cash Flow	-7.04B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 59.42%, with operating and profit margins of 39.15% and 32.10%.

Gross Margin	59.42%
Operating Margin	39.15%
Pretax Margin	32.94%
Profit Margin	32.10%
EBITDA Margin	42.44%
EBIT Margin	39.15%
FCF Margin	n/a

Dividends & Yields

Novavax does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-16.16%
Shareholder Yield	-16.16%
Earnings Yield	30.83%
FCF Yield	-34.62%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Novavax has an Altman Z-Score of -2.23 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-2.23
Piotroski F-Score	5